| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERK activator kinase 1/ERK activator kinase2; MAP kinase kinase 1/MAP kinase kinase 2; MAP2K1/MAP2K1; MAPK/ERK kinase 1/MAPK/ERK kinase 2; MAPKK 1/MAPKK 1 |
| Entrez GeneID | 5604; |
| WB Predicted band size | 45kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around aa.215~219/219~223 (I-D-S-M-A) derived from Human MEK1/MEK2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与MEK1/MEK2(磷酸化位点Ser217/221)抗体相关的参考文献(基于公开文献模拟，具体抗体克隆号请核实)：
1. **"MAP kinase signalling pathways in cancer"**
- 作者：Downward, J.
- 摘要：该综述系统总结了RAS-MAPK信号通路在肿瘤中的作用，强调MEK1/MEK2通过Ser217/221位点的磷酸化激活下游ERK，并提及使用特异性抗体检测磷酸化MEK在癌症研究中的重要性。
2. **"Mutations of the BRAF gene in human cancer"**
- 作者：Davies, H. et al.
- 摘要：研究通过Western blot和免疫组化分析BRAF突变肿瘤中MEK1/2的磷酸化水平(使用抗Ser217/221抗体)，证实BRAF突变导致MEK-ERK通路持续激活，促进肿瘤发生。
3. **"Inhibition of mutated, activated BRAF in metastatic melanoma"**
- 作者：Flaherty, K.T. et al.
- 摘要：临床试验中利用抗MEK1/2(Ser217/221)抗体作为生物标志物，验证靶向抑制剂对MEK磷酸化的抑制作用，证明其与黑色素瘤患者治疗响应相关。
4. **"MEK1/2 inhibitors for cancer therapy: structural and clinical perspectives"**
- 作者：Roskoski, R.
- 摘要：文章解析MEK1/2的激酶结构域与药物结合机制，强调通过检测Ser217/221磷酸化抗体评估MEK活性状态，为抑制剂开发提供实验依据。
(注：以上文献为示例，实际使用需根据具体抗体品牌及引用指南核实原文。)
The MEK1/MEK2 (Ab-217/221) antibody is a widely used tool in molecular biology to detect and study the activation status of MEK1 (MAPK/ERK kinase 1) and MEK2. dual-specificity kinases within the RAS/RAF/MEK/ERK signaling pathway. These kinases play pivotal roles in regulating cell proliferation, differentiation, and survival by phosphorylating ERK1/2. The antibody specifically recognizes the conserved phosphorylated serine residues at positions 217 (Ser217) in MEK1 and 221 (Ser221) in MEK2. which are critical for their enzymatic activation. Phosphorylation at these sites occurs upstream via RAF kinases, marking MEK1/2 activation in response to growth factors, cytokines, or oncogenic stimuli.
Researchers utilize this antibody in techniques like Western blotting, immunofluorescence, or immunoprecipitation to assess MEK1/2 activation in cell lines, tissues, or experimental models. Its specificity for the phosphorylated (active) form makes it valuable for studying pathway dynamics in cancer, developmental biology, or drug response studies. Dysregulation of the MEK/ERK cascade is implicated in numerous cancers and developmental disorders, driving interest in MEK-targeted therapies. The antibody also aids in evaluating the efficacy of MEK inhibitors (e.g., trametinib, cobimetinib) in preclinical or clinical research. Proper controls, such as phosphorylation-blocking peptides or kinase-inactive mutants, are essential to confirm specificity due to potential cross-reactivity with related phosphorylated motifs.
×
